BR112015023031A2 - métodos de conservação e melhoria da função múscular - Google Patents
métodos de conservação e melhoria da função múscularInfo
- Publication number
- BR112015023031A2 BR112015023031A2 BR112015023031A BR112015023031A BR112015023031A2 BR 112015023031 A2 BR112015023031 A2 BR 112015023031A2 BR 112015023031 A BR112015023031 A BR 112015023031A BR 112015023031 A BR112015023031 A BR 112015023031A BR 112015023031 A2 BR112015023031 A2 BR 112015023031A2
- Authority
- BR
- Brazil
- Prior art keywords
- muscle function
- methods
- conservation
- improvement
- egcg
- Prior art date
Links
- 230000004220 muscle function Effects 0.000 title abstract 6
- 230000007423 decrease Effects 0.000 abstract 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 abstract 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 1
- 101600082430 Homo sapiens Vascular endothelial growth factor A (isoform VEGF165) Proteins 0.000 abstract 1
- 108010056852 Myostatin Proteins 0.000 abstract 1
- 102300041083 Vascular endothelial growth factor A isoform VEGF165 Human genes 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/50—Preservation of non-alcoholic beverages by irradiation or electric treatment without heating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Abstract
resumo métodos de conservação e melhoria da função múscular a presente invenção fornece métodos de redução do declínio da função muscular e melhoria da função muscular em um sujeito. os métodos utilizam uma quantidade eficaz de epigalocatequina-3-galato (egcg) para aumentar o nível do fator a de crescimento endotelial vascular (vegf) muscular para diminuir os níveis de miostatina, ou ambos, e, assim, diminuir o declínio da função muscular ou me-lhorar a função muscular. o egcg pode ser fornecido como parte de uma composi-ção nutricional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792489P | 2013-03-15 | 2013-03-15 | |
US201361823832P | 2013-05-15 | 2013-05-15 | |
PCT/US2014/028879 WO2014144458A1 (en) | 2013-03-15 | 2014-03-14 | Methods of maintaining and improving muscle function |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023031A2 true BR112015023031A2 (pt) | 2017-07-18 |
Family
ID=50555279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023031A BR112015023031A2 (pt) | 2013-03-15 | 2014-03-14 | métodos de conservação e melhoria da função múscular |
Country Status (11)
Country | Link |
---|---|
US (1) | US9844531B2 (pt) |
EP (1) | EP2986158A1 (pt) |
JP (1) | JP2016517438A (pt) |
CN (1) | CN105431057A (pt) |
BR (1) | BR112015023031A2 (pt) |
CA (1) | CA2903565A1 (pt) |
HK (1) | HK1221611A1 (pt) |
MX (1) | MX2015013000A (pt) |
PH (1) | PH12015502167A1 (pt) |
SG (1) | SG11201507135XA (pt) |
WO (1) | WO2014144458A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3091859A1 (en) * | 2013-12-18 | 2016-11-16 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
WO2016044272A1 (en) * | 2014-09-16 | 2016-03-24 | Abbott Laboratories | Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract |
US20190126075A1 (en) * | 2015-09-30 | 2019-05-02 | Kyodo Milk Industry Co., Ltd. | Food and drink product containing poorly digestible compound and colonic-hydrogen-gas producing agent |
JP7401969B2 (ja) * | 2016-01-13 | 2023-12-20 | メタボリック・テクノロジーズ,インコーポレーテッド | 関節安定性のためのβ-ヒドロキシ-β-メチルブチレート(HMB)の組成物および使用方法 |
AU2017270131B2 (en) * | 2016-05-27 | 2023-03-09 | Société des Produits Nestlé S.A. | Nutritional composition for treating or preventing impaired mobility |
US20180110745A1 (en) * | 2016-10-21 | 2018-04-26 | Metabolic Technologies, Inc. | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics |
EP3599898B1 (en) | 2017-03-31 | 2022-08-17 | Abbott Laboratories | Liquid nutritional compositions containing oxidizable fish oil, rosmarinic acid and ferric iron |
US20200163370A1 (en) | 2017-08-03 | 2020-05-28 | Abbott Laboratories | Liquid nutritional compositions including green tea extract and iron |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
KR102281263B1 (ko) * | 2019-03-12 | 2021-07-26 | 주식회사 비티씨 | 갈릭산, 에피카테킨(ec), 및 에피갈로카테킨(egc)의 함량이 증가된 카테킨 효소처리물 및 이의 제조방법 |
US20210228657A1 (en) * | 2019-04-23 | 2021-07-29 | Glac Biotech Co., Ltd. | Food composition and pharmaceutical composition used for increasing exercise performance and ameliorating fatigue |
JP2022538154A (ja) * | 2019-07-05 | 2022-08-31 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びビタミンを使用する組成物及び方法 |
WO2021015585A2 (ko) * | 2019-07-25 | 2021-01-28 | 고려대학교 산학협력단 | 쌍별귀뚜라미 분말 또는 이의 추출물의 제조방법, 이를 포함하는 식품 조성물 및 이의 활용 |
CN111000233A (zh) * | 2019-11-28 | 2020-04-14 | 湖南农业大学 | Ecg作为健肌功能成分的应用 |
CN110839890B (zh) * | 2019-12-03 | 2022-06-21 | 湖南农业大学 | 一种茶黄素健肌的膳食营养补充剂的及其制备方法 |
WO2021072450A2 (en) * | 2020-03-10 | 2021-04-15 | The Regents Of The University Of California | Novel nutrients to enhance load-induced muscle hypertrophy |
KR20220015769A (ko) * | 2020-07-31 | 2022-02-08 | 고려대학교 산학협력단 | 그릴루스 비마쿨라투스를 유효성분으로 포함하는 근위축증의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK112399A3 (en) | 1997-02-21 | 2000-12-11 | Abbott Lab | Methods and compositions for reducing the incidence of necrotizing enterocolitis |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6811801B2 (en) | 2001-12-12 | 2004-11-02 | Abbott Laboratories | Methods and compositions for brightening the color of thermally processed nutritionals |
CA2470603A1 (en) | 2001-12-19 | 2003-07-03 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US20040138118A1 (en) | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7083813B2 (en) | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
JP2006131512A (ja) | 2004-11-02 | 2006-05-25 | Pharma Foods International Co Ltd | アディポネクチン分泌促進組成物および該組成物を含有する飲食品 |
FR2882896B1 (fr) | 2005-03-14 | 2007-05-04 | Larena Sa | Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
CN101978958A (zh) * | 2005-10-14 | 2011-02-23 | 帝斯曼知识产权资产管理有限公司 | 用于治疗肌肉消瘦的营养药物性组合物 |
US20090163579A1 (en) | 2005-10-14 | 2009-06-25 | Daniel Raederstorff | Novel use of nutraceutical compositions |
US20070104807A1 (en) * | 2005-11-08 | 2007-05-10 | Gardiner Paul T | Compositions and methods for weight-loss and weight-loss maintenance in daytime and nighttime formulation |
KR101558231B1 (ko) | 2006-05-01 | 2015-10-08 | (주)아모레퍼시픽 | (-)카테친을 함유하는 아디포넥틴 발현 증강제 |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
JP2008013473A (ja) * | 2006-07-05 | 2008-01-24 | Kao Corp | 筋機能低下抑制剤 |
US8962678B2 (en) | 2006-07-05 | 2015-02-24 | Kao Corporation | Senescence inhibitor |
WO2008004333A1 (fr) | 2006-07-05 | 2008-01-10 | Kao Corporation | Agent pour l'amélioration de la puissance musculaire |
EP1961310A1 (en) | 2007-02-01 | 2008-08-27 | DSMIP Assets B.V. | Novel use of (-) -epigallocatechin gallate |
US20100210692A1 (en) | 2007-03-28 | 2010-08-19 | Farmer Stephen R | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
LT2170396T (lt) | 2007-08-03 | 2017-03-10 | Summit (Oxford) Limited | Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui |
JP2009120491A (ja) | 2007-11-12 | 2009-06-04 | Tsujido Kagaku Kk | アディポネクチン産生促進剤 |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
EA023244B1 (ru) | 2009-04-10 | 2016-05-31 | Хаян Ки | Способ предотвращения старения клеток |
US20100303937A1 (en) | 2009-06-01 | 2010-12-02 | Michael Farber | Novel composition to increase testosterone levels |
EP2440201A1 (en) | 2009-06-10 | 2012-04-18 | Energy4life Ag | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
AU2010274125B2 (en) | 2009-07-20 | 2015-11-05 | Société des Produits Nestlé S.A. | Methods of attenuating the loss of functional status |
CA2787002A1 (en) | 2010-01-25 | 2011-07-28 | Concept Medical Research Private Limited | A method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent |
WO2013142816A1 (en) | 2012-03-23 | 2013-09-26 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders |
WO2014028607A1 (en) | 2012-08-14 | 2014-02-20 | Abbott Laboratories | Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics |
EP2903458B1 (en) | 2012-10-04 | 2018-09-05 | Abbott Laboratories | Methods for enhancing the effect of egcg on mitigating skeletal muscle loss |
-
2014
- 2014-03-14 JP JP2016502929A patent/JP2016517438A/ja active Pending
- 2014-03-14 BR BR112015023031A patent/BR112015023031A2/pt not_active IP Right Cessation
- 2014-03-14 CN CN201480027811.9A patent/CN105431057A/zh active Pending
- 2014-03-14 CA CA2903565A patent/CA2903565A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/028879 patent/WO2014144458A1/en active Application Filing
- 2014-03-14 EP EP14719586.1A patent/EP2986158A1/en not_active Withdrawn
- 2014-03-14 US US14/776,972 patent/US9844531B2/en not_active Expired - Fee Related
- 2014-03-14 MX MX2015013000A patent/MX2015013000A/es unknown
- 2014-03-14 SG SG11201507135XA patent/SG11201507135XA/en unknown
-
2015
- 2015-09-15 PH PH12015502167A patent/PH12015502167A1/en unknown
-
2016
- 2016-08-19 HK HK16109947.7A patent/HK1221611A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014144458A1 (en) | 2014-09-18 |
US9844531B2 (en) | 2017-12-19 |
CN105431057A (zh) | 2016-03-23 |
EP2986158A1 (en) | 2016-02-24 |
HK1221611A1 (zh) | 2017-06-09 |
PH12015502167A1 (en) | 2016-01-25 |
MX2015013000A (es) | 2015-12-01 |
SG11201507135XA (en) | 2015-10-29 |
CA2903565A1 (en) | 2014-09-18 |
JP2016517438A (ja) | 2016-06-16 |
US20160038457A1 (en) | 2016-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023031A2 (pt) | métodos de conservação e melhoria da função múscular | |
CU20130137A7 (es) | Derivados de ácido 3- fenilpropiónico ramificados y su uso | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
CU20140025A7 (es) | Pirimidinas anilladas sustituidas | |
BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
DOP2016000006A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
CL2015002677A1 (es) | Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial. | |
EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
JP2012036176A5 (pt) | ||
ECSP15034601A (es) | Composiciones nutricionales que contienen treonato de magnesio, y sus usos | |
BR112013011259A2 (pt) | condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3 | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
BR112014000542A2 (pt) | composições de peroxidase eosinofílica e métodos de uso das mesmas | |
BR112016011472A2 (pt) | tienopirimidinas como inibidores de mknk1 e mknk2 | |
AR093632A1 (es) | Tratamiento de cafe soluble | |
MX369223B (es) | Composiciones de protector solar. | |
BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
FR2977256B1 (fr) | Compositions de 2,4,4,4-tetrafluorobut-1-ene et de cis-1,1,1,4,4,4-hexafluorobut-2-ene | |
IN2014KN02914A (pt) | ||
BR112018009396A2 (pt) | composição bacteriana para uso em atenuar o declínio de desempenho após exercício | |
BR112017026834A2 (pt) | composição compreendendo vitaminas b e vitaminas c e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |